Disease · MONDO_0005086
Comparisons in its trials154
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 154
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Everolimus vs Placebo: deaths from any cause | 139 of 755 | 151 of 744 | 1,499 | NCT01120249 | Trial comparisons |
| Everolimus vs Placebo: serious adverse events | 154 of 740 | 68 of 723 | 1,463 | NCT01120249 | Trial comparisons |
| Nivolumab + Ipilimumab vs Sunitinib: deaths from any cause | 159 of 547 | 202 of 535 | 1,082 | NCT02231749 | Trial comparisons |
| Nivolumab + Ipilimumab vs Sunitinib: serious adverse events | 305 of 547 | 213 of 535 | 1,082 | NCT02231749 | Trial comparisons |
| Pembrolizumab vs Placebo: deaths from any cause | 18 of 496 | 33 of 498 | 994 | NCT03142334 | Trial comparisons |
| Pembrolizumab vs Placebo: serious adverse events | 100 of 488 | 56 of 496 | 984 | NCT03142334 | Trial comparisons |
| Sunitinib vs Atezolizumab + Bevacizumab: deaths from any cause | 270 of 461 | 263 of 454 | 915 | NCT02420821 | Trial comparisons |
| Sunitinib vs Atezolizumab + Bevacizumab: serious adverse events | 169 of 446 | 191 of 451 | 897 | NCT02420821 | Trial comparisons |
| Avelumab + Axitinib vs Sunitinib: deaths from any cause | 284 of 442 | 296 of 444 | 886 | NCT02684006 | Trial comparisons |
| Avelumab + Axitinib vs Sunitinib: Number of Participants Who Discontinued Treatment Due to Toxicity | 136 of 434 | 65 of 439 | 873 | NCT02684006 | Trial comparisons |
| Avelumab + Axitinib vs Sunitinib: serious adverse events | 231 of 434 | 166 of 439 | 873 | NCT02684006 | Trial comparisons |
| Pembrolizumab + Axitinib vs Sunitinib: deaths from any cause | 59 of 432 | 97 of 429 | 861 | NCT02853331 | Trial comparisons |
| Pembrolizumab + Axitinib vs Sunitinib: Number of Participants Who Discontinued Study Drug Due to an AE | 131 of 429 | 59 of 425 | 854 | NCT02853331 | Trial comparisons |
| Pembrolizumab + Axitinib vs Sunitinib: Number of Participants Who Experienced an Adverse Event (AE) | 422 of 429 | 423 of 425 | 854 | NCT02853331 | Trial comparisons |
| Pembrolizumab + Axitinib vs Sunitinib: serious adverse events | 173 of 429 | 133 of 425 | 854 | NCT02853331 | Trial comparisons |
| Cabozantinib + Nivolumab + Ipilimumab vs Placebo + Nivolumab + Ipilimumab: deaths from any cause | 224 of 426 | 217 of 423 | 849 | NCT03937219 | Trial comparisons |
| Cabozantinib + Nivolumab + Ipilimumab vs Placebo + Nivolumab + Ipilimumab: serious adverse events | 272 of 426 | 257 of 423 | 849 | NCT03937219 | Trial comparisons |
| Arm A (Nephrectomy + Nivolumab) vs Arm B (Nephrectomy Only): deaths from any cause | 48 of 404 | 40 of 415 | 819 | NCT03055013 | Trial comparisons |
| Avelumab + Axitinib vs Sunitinib: Number of Participants With Positive PD-L1 Biomarker Expression in Pre-treatment Tumor Tissue | 266 of 397 | 288 of 407 | 804 | NCT02684006 | Trial comparisons |
| NIVOLUMAB vs EVEROLIMUS: deaths from any cause | 324 of 406 | 342 of 397 | 803 | NCT01668784 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005086/comparisons